Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Eisai Ltd ADR (ESALY)

Eisai Ltd ADR (ESALY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 17,638,976
  • Shares Outstanding, K 286,766
  • Annual Sales, $ 6,730 M
  • Annual Income, $ 426,790 K
  • EBIT $ N/A
  • EBITDA $ N/A
  • 60-Month Beta 0.31
  • Price/Sales 2.67
  • Price/Cash Flow 22.94
  • Price/Book 2.88
  • Price/Earnings ttm 72.22
  • Earnings Per Share ttm 0.87
  • Most Recent Earnings $0.09 on 11/07/22
  • Next Earnings Date 02/02/23
  • Annual Dividend & Yield 0.88 (1.43%)
  • Most Recent Dividend 0.440 on 09/27/22
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/22
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year 0.43
  • Growth Rate Est. (year over year) +232,225.58%

Price Performance

See More
Period Period Low Period High Performance
1-Month
60.4000 +1.84%
on 01/05/23
68.8500 -10.66%
on 01/06/23
-4.8000 (-7.24%)
since 12/30/22
3-Month
56.8800 +8.14%
on 11/09/22
73.9035 -16.77%
on 12/05/22
+1.0100 (+1.67%)
since 10/28/22
52-Week
36.8800 +66.78%
on 06/17/22
73.9035 -16.77%
on 12/05/22
+11.2000 (+22.26%)
since 01/28/22

Most Recent Stories

More News
Biogen's Just Made Its Biggest Acquisition. Here's What You Need to Know.

Biogen also recently announced a plan to cut costs and focus investment on high-growth areas.

RETA : 172.36 (+0.02%)
ESALY : 61.5100 (-2.11%)
BIIB : 168.28 (-2.18%)
Biogen Shares Fall After FDA Approval Of Alzheimer's Drug Leqembi

Biogen's shares decline after approval of Alzheimer's treatment Leqembi, which modestly slows cognitive decline. Analysts see hurdles to the rollout.

ESAIY : 8.1300 (-0.61%)
BIIB : 168.28 (-2.18%)
LLY : 818.86 (-1.63%)
XLV : 147.22 (-1.39%)
ESALY : 61.5100 (-2.11%)
Why Anavex Life Sciences Stock Bolted Higher in January

The biotech's shares have been steadily leaking higher following positive late-stage Alzheimer's disease trial results.

BIIB : 168.28 (-2.18%)
ESALY : 61.5100 (-2.11%)
AVXL : 9.02 (-1.42%)
Lecanemab Receives Priority Review Status in Japan

Lecanemab Receives Priority Review Status in Japan

ESALY : 61.5100 (-2.11%)
Is Biogen Stock a No-Brainer Buy After Eli Lilly's Alzheimer's Disease Setback?

Lilly's FDA rejection puts Biogen and its partner Eisai in the driver's seat in the Alzheimer's disease drug market.

LLY : 818.86 (-1.63%)
ESALY : 61.5100 (-2.11%)
BIIB : 168.28 (-2.18%)
Why Biogen's Stock Isn't Soaring Since Its Alzheimer's Drug Got Approval

The Food and Drug Administration authorized Leqembi under an accelerated approval pathway this month.

ESALY : 61.5100 (-2.11%)
BIIB : 168.28 (-2.18%)
This Monumental Breakthrough Could Turn the World Upside Down -- and Make Some Investors Filthy Rich

The fountain of youth might not be a myth in the future.

GOOG : 183.32 (+0.74%)
GOOGL : 181.62 (+0.70%)
ABBV : 171.09 (-1.91%)
UNH : 614.67 (-1.69%)
BIIB : 168.28 (-2.18%)
ESALY : 61.5100 (-2.11%)
Should You Buy Biogen Stock After Its Latest Alzheimer's Disease Drug Approval?

There's more to the story with Biogen after receiving good news for Leqembi.

BIIB : 168.28 (-2.18%)
ESALY : 61.5100 (-2.11%)
Eisai Submits Supplemental Biologics License Application to FDA for Traditional Approval of LEQEMBI (lecanemab-irmb) for the Treatment of Alzheimer's Disease

Eisai Submits Supplemental Biologics License Application to FDA for Traditional Approval of LEQEMBI (lecanemab-irmb) for the Treatment of Alzheimer's Disease

ESALY : 61.5100 (-2.11%)
FDA Approves LEQEMBI (lecanemab-irmb) Under the Accelerated Approval Pathway for the Treatment of Alzheimer's Disease

FDA Approves LEQEMBI (lecanemab-irmb) Under the Accelerated Approval Pathway for the Treatment of Alzheimer's Disease

ESALY : 61.5100 (-2.11%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Eisai Co LTD is involved in the Biotechnology and Drug Industry. Their principle activities are the manufacture and sale of pharmaceutical products. Operations are carried out through the following divisions: Pharmaceuticals: veterinary drugs other food additives, livestock feed and pharmaceutical production...

See More

Key Turning Points

3rd Resistance Point 65.1567
2nd Resistance Point 64.2233
1st Resistance Point 62.8667
Last Price 61.5100
1st Support Level 60.5767
2nd Support Level 59.6433
3rd Support Level 58.2867

See More

52-Week High 73.9035
Last Price 61.5100
Fibonacci 61.8% 59.7605
Fibonacci 50% 55.3918
Fibonacci 38.2% 51.0230
52-Week Low 36.8800

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar